Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Share Buy Back

1 Jun 2011 07:00

RNS Number : 6150H
Ovoca Gold PLC
01 June 2011
 

Ovoca Gold PLC

1 June 2011

 

Ovoca Gold Plc ("Ovoca" or the "Company")

Commencement of buy back program

 

 

Ovoca announces that on 31 May 2011 it commenced an on-market share buy back programme.

 

Ovoca has in place the necessary authorities to allow the Company purchase up to 10 per cent. of its issued share capital by way of on-market share buy backs. The Company intends that share buy backs will only be executed when appropriate financial and stock market conditions prevail and when management determines that share purchases are in the best interests of the Company and its Shareholders as a whole.

 

On 31 May 2011 Ovoca acquired 35,000 ordinary shares of €0.125 each ("Ordinary Shares") of the Company at an average price of GBP31p. Ovoca intends to hold these shares as treasury stock. Ovoca now has a total of 88,423,806 Ordinary Shares in issue excluding treasury shares and 35,000 Ordinary Shares held in treasury.

 

Tim McCutcheon, CEO, comments: "Ovoca Gold has several investments in gold mining equities, which gives shareholders exposure to gold investment before we commence our own gold production (anticipated in 2013). As Ovoca's market value is at a discount to the Company's cash and securities position, Ovoca stock is a welcome addition to our overall portfolio."

 

 

Notes to Editors

 

Ovoca Gold PLC ("Ovoca" or "the Company") is a mineral exploration and mine development company listed on the AIM market of the London Stock Exchange (Ticker: OVG) and on the ESM market of the Irish Stock Exchange (Ticker: OVX). The Company's principal activity is gold exploration in the Magadan Region of the Russian Federation. Previously Ovoca acquired, developed and sold to JSC Polymetal the Goltsovoye silver project located in the Magadan Region. Currently, Ovoca is aggressively exploring and developing its 100 per cent owned Stakhanovsky, Rassoshinskaya and Nevsko-Pestrinskoye licenses.

 

Stakhanovsky is located approximately 40 kilometres north of Susuman, the second largest city in the Magadan region. It is accessible by year-round road and there is power infrastructure on site. Stakhanovsky's initial independently established resource was announced in an RNS on 2 February 2011 and is available on the Company's website. The Company intends to put Stakhanovsky into production by 2013.

 

Rassoshinskaya is in the North Eastern part of the Magadan Region about 200 kilometres from the town of Seimchan. There is no nearby infrastructure. Rassoshinskaya hosts an epithermal gold deposit named Olcha, which is the focus of Ovoca's exploration program. Olcha and nearby satellite deposits have the potential to host a high grade multi-million ounce gold resource. Olcha's initial independently established resource was announced in an RNS on 22 June 2010 and is available on the Company's website.

 

Nevsko-Pestrinskoye is located in the central part of the Magadan region near the town of Omsukchan. A year-round road and powerline are near the site. The license completely surrounds the Goltsovoye silver deposit, which was owned by the Company from 2006 - 2009 and sold to JSC Polymetal for US$47.7 million at the time of closing. Ovoca intends to investigate and explore known mineral occurrences that extend beyond the Goltsovoye license area onto Nevsko-Pestrinskoye.

 

 

Ovoca Gold Plc

 

Timothy McCutcheon +7 495 916 6029 tim.mccutcheon@ovocagold.com 

 

Davy

 

John Frain +353 1 679 6363

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
POSWGUAGAUPGGRG
Date   Source Headline
29th Jul 20227:00 amRNSCompletion of Enrollment in Phase II Study
30th Jun 20227:00 amRNSAnnual Financial Report
7th Mar 20229:00 amRNSStatement re Russian Business Operations
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
22nd Feb 20223:30 pmRNSRussian Marketing Authorisation for Orenetide
31st Jan 20227:00 amRNSBoard Changes and Update
30th Dec 20217:00 amRNSDirectorate Change
4th Nov 20213:53 pmRNSHolding(s) in Company
4th Nov 20213:50 pmRNSDirector/PDMR Shareholding
4th Nov 20213:46 pmRNSBoard Change
14th Sep 20217:00 amRNSInterim Results
29th Jul 20215:00 pmRNSResult of AGM
24th Jun 20217:00 amRNSAnnual Report and Notice of AGM
10th Mar 20217:00 amRNSMigration of Participating Securities
16th Feb 20212:00 pmRNSResult of EGM
29th Jan 20217:00 amRNSFirst Patient Enrolled in Phase II Study - BP-101
25th Jan 20213:30 pmRNSNotice of EGM
5th Jan 20217:00 amRNSRe-Filing of Marketing Authorisation Application
17th Dec 20202:45 pmRNSResult of AGM
27th Nov 20203:08 pmRNSNotice of AGM
9th Oct 20207:00 amRNSAppointment of Chief Business Officer
2nd Oct 202011:06 amRNSSecond Price Monitoring Extn
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20209:05 amRNSSecond Price Monitoring Extn
2nd Oct 20209:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSUpdate re Russian Marketing Authorisation
28th Sep 20207:00 amRNSDeath of a Director
21st Sep 20207:00 amRNSInterim Results
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
26th Jun 20207:00 amRNSAnnual Report
14th Apr 20202:05 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSAcquisition of Remaining Minority Interest in IVIX
7th Nov 201912:45 pmRNSAttendance at Bio-Europe Conference
16th Sep 20197:00 amRNSInterim Results
12th Sep 20197:00 amRNSFiling of Marketing Authorisation Application
28th Aug 20197:00 amRNSDirectorate Change
8th Aug 20194:14 pmRNSResult of AGM
8th Aug 20199:05 amRNSSecond Price Monitoring Extn
8th Aug 20199:00 amRNSPrice Monitoring Extension
8th Aug 20197:00 amRNSAGM Statement
26th Jul 20197:00 amRNSDirectorate Change
25th Jul 20194:41 pmRNSSecond Price Monitoring Extn
25th Jul 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20197:00 amRNSUS and EU Clinical Development Plans
29th Mar 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSOperational Update & Additional Investment in IVIX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.